vs
agilon health, inc.（AGL）与BioRestorative Therapies, Inc.（BRTX）财务数据对比。点击上方公司名可切换其他公司
agilon health, inc.的季度营收约是BioRestorative Therapies, Inc.的80076.1倍（$1.6B vs $19.6K）。agilon health, inc.净利率更高（-12.0% vs -16365.5%，领先16353.5%）。agilon health, inc.同比增速更快（3.1% vs -54.7%）。BioRestorative Therapies, Inc.自由现金流更多（$-2.5M vs $-23.5M）。过去两年agilon health, inc.的营收复合增速更高（-1.1% vs -25.2%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
BioRestorative Therapies, Inc.是一家临床阶段生物技术企业，专注于创新再生医学疗法的研发，核心管线覆盖慢性腰痛、代谢类疾病等未被满足的医疗需求领域，主要面向北美市场，推进细胞类创新候选治疗产品的临床开发工作。
AGL vs BRTX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $19.6K |
| 净利润 | $-188.9M | $-3.2M |
| 毛利率 | — | 91.7% |
| 营业利润率 | -12.3% | -19516.8% |
| 净利率 | -12.0% | -16365.5% |
| 营收同比 | 3.1% | -54.7% |
| 净利润同比 | -78.5% | -96.0% |
| 每股收益（稀释后） | — | $-0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $1.6B | $19.6K | ||
| Q3 25 | $1.4B | $11.8K | ||
| Q2 25 | $1.4B | $303.3K | ||
| Q1 25 | $1.5B | $25.0K | ||
| Q4 24 | $1.5B | $43.3K | ||
| Q3 24 | $1.5B | $233.6K | ||
| Q2 24 | $1.5B | $89.1K | ||
| Q1 24 | $1.6B | $35.0K |
| Q4 25 | $-188.9M | $-3.2M | ||
| Q3 25 | $-110.2M | $-3.0M | ||
| Q2 25 | $-104.4M | $-2.7M | ||
| Q1 25 | $12.1M | $-5.3M | ||
| Q4 24 | $-105.8M | $-1.6M | ||
| Q3 24 | $-117.6M | $-1.1M | ||
| Q2 24 | $-30.7M | $-4.0M | ||
| Q1 24 | $-6.1M | $-2.2M |
| Q4 25 | — | 91.7% | ||
| Q3 25 | — | 10.4% | ||
| Q2 25 | — | 97.1% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 92.3% | ||
| Q3 24 | — | 92.2% | ||
| Q2 24 | — | 92.7% | ||
| Q1 24 | — | 100.0% |
| Q4 25 | -12.3% | -19516.8% | ||
| Q3 25 | -9.1% | -31432.3% | ||
| Q2 25 | -8.3% | -1089.8% | ||
| Q1 25 | -1.4% | -19230.1% | ||
| Q4 24 | -7.1% | -6212.8% | ||
| Q3 24 | -9.2% | -979.0% | ||
| Q2 24 | -2.9% | -2770.8% | ||
| Q1 24 | -0.4% | -11740.7% |
| Q4 25 | -12.0% | -16365.5% | ||
| Q3 25 | -7.7% | -25748.1% | ||
| Q2 25 | -7.5% | -875.8% | ||
| Q1 25 | 0.8% | -21359.2% | ||
| Q4 24 | -6.9% | -3778.6% | ||
| Q3 24 | -8.1% | -467.2% | ||
| Q2 24 | -2.1% | -4521.4% | ||
| Q1 24 | -0.4% | -6352.2% |
| Q4 25 | — | $-0.31 | ||
| Q3 25 | — | $-0.33 | ||
| Q2 25 | — | $-0.30 | ||
| Q1 25 | — | $-0.64 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | — | $-0.13 | ||
| Q2 24 | — | $-0.50 | ||
| Q1 24 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $3.0M |
| 总债务越低越好 | $35.0M | — |
| 股东权益账面价值 | $126.7M | $356.7K |
| 总资产 | $1.3B | $4.1M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
| Q4 25 | $173.7M | $3.0M | ||
| Q3 25 | $171.7M | $4.5M | ||
| Q2 25 | $171.4M | $7.4M | ||
| Q1 25 | $136.9M | $9.1M | ||
| Q4 24 | $188.2M | $10.7M | ||
| Q3 24 | $148.2M | $13.1M | ||
| Q2 24 | $109.5M | $14.7M | ||
| Q1 24 | $111.7M | $16.4M |
| Q4 25 | $35.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $126.7M | $356.7K | ||
| Q3 25 | $306.1M | $2.2M | ||
| Q2 25 | $408.9M | $4.8M | ||
| Q1 25 | $500.3M | $6.1M | ||
| Q4 24 | $471.0M | $8.5M | ||
| Q3 24 | $574.9M | $10.0M | ||
| Q2 24 | $676.6M | $10.8M | ||
| Q1 24 | $689.3M | $14.5M |
| Q4 25 | $1.3B | $4.1M | ||
| Q3 25 | $1.6B | $5.6M | ||
| Q2 25 | $1.7B | $8.5M | ||
| Q1 25 | $1.9B | $10.3M | ||
| Q4 24 | $1.7B | $12.3M | ||
| Q3 24 | $2.1B | $14.6M | ||
| Q2 24 | $2.2B | $16.1M | ||
| Q1 24 | $2.3B | $18.0M |
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $-2.4M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | $-2.5M |
| 自由现金流率自由现金流/营收 | -1.5% | -12728.8% |
| 资本支出强度资本支出/营收 | 0.2% | 406.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-119.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-20.5M | $-2.4M | ||
| Q3 25 | $-18.2M | $-2.9M | ||
| Q2 25 | $-35.1M | $-2.7M | ||
| Q1 25 | $-32.0M | $-2.8M | ||
| Q4 24 | $16.4M | $-2.3M | ||
| Q3 24 | $-7.7M | $-1.7M | ||
| Q2 24 | $-18.7M | $-1.9M | ||
| Q1 24 | $-47.8M | $-2.3M |
| Q4 25 | $-23.5M | $-2.5M | ||
| Q3 25 | $-21.3M | — | ||
| Q2 25 | $-38.3M | — | ||
| Q1 25 | $-35.8M | $-2.8M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $-11.2M | $-1.8M | ||
| Q2 24 | $-22.0M | — | ||
| Q1 24 | $-50.9M | — |
| Q4 25 | -1.5% | -12728.8% | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -2.3% | -11260.7% | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | -0.8% | -752.6% | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -3.2% | — |
| Q4 25 | 0.2% | 406.5% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q1 25 | 0.3% | 145.6% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | 25.0% | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2.64× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
BRTX
暂无分部数据
